NZ213501A - Pharmaceutical compositions containing alpha-interferons - Google Patents
Pharmaceutical compositions containing alpha-interferonsInfo
- Publication number
- NZ213501A NZ213501A NZ213501A NZ21350185A NZ213501A NZ 213501 A NZ213501 A NZ 213501A NZ 213501 A NZ213501 A NZ 213501A NZ 21350185 A NZ21350185 A NZ 21350185A NZ 213501 A NZ213501 A NZ 213501A
- Authority
- NZ
- New Zealand
- Prior art keywords
- leu
- ser
- glu
- gln
- ile
- Prior art date
Links
- 229940047124 interferons Drugs 0.000 title description 7
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940079322 interferon Drugs 0.000 claims description 24
- 206010012735 Diarrhoea Diseases 0.000 claims description 11
- 102000014150 Interferons Human genes 0.000 claims description 9
- 108010050904 Interferons Proteins 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 6
- 210000004051 gastric juice Anatomy 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 10
- NDYNTQWSJLPEMK-WDSKDSINSA-N Met-Cys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CS)C(O)=O NDYNTQWSJLPEMK-WDSKDSINSA-N 0.000 claims 3
- FTSAJSADJCMDHH-CIUDSAMLSA-N Asn-Lys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N FTSAJSADJCMDHH-CIUDSAMLSA-N 0.000 claims 2
- GXXWTNKNFFKTJB-NAKRPEOUSA-N Arg-Ile-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O GXXWTNKNFFKTJB-NAKRPEOUSA-N 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 description 8
- 108010047761 Interferon-alpha Proteins 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000010353 genetic engineering Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 241000894007 species Species 0.000 description 2
- HZYFHQOWCFUSOV-IMJSIDKUSA-N Asn-Asp Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O HZYFHQOWCFUSOV-IMJSIDKUSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- -1 dextrose anhydride Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19843434345 DE3434345A1 (de) | 1984-09-19 | 1984-09-19 | Verwendung von (alpha)-interferonen zur bekaempfung von durchfaellen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ213501A true NZ213501A (en) | 1988-04-29 |
Family
ID=6245770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ213501A NZ213501A (en) | 1984-09-19 | 1985-09-17 | Pharmaceutical compositions containing alpha-interferons |
Country Status (12)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1867340A4 (en) * | 2005-03-10 | 2009-12-23 | Hayashibara Biochem Lab | THERAPEUTIC AGENT FOR TREATING DISEASES IN THE BOVINE DIGESTIVE SYSTEM |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL47592A0 (en) * | 1975-06-27 | 1975-08-31 | Res Prod Rehovot Ltd | Controlled drug releasing preparation |
| ES8302778A1 (es) * | 1980-11-10 | 1983-02-01 | Genentech Inc | Un procedimiento para producir un polipeptido antiviral. |
| IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US5098703A (en) * | 1982-01-15 | 1992-03-24 | Cetus Corporation | Interferon-alpha 76 |
| US4820515A (en) * | 1982-12-13 | 1989-04-11 | Texas A&M University System | Method of using interferon in low dosage to regulate appetite and efficiency of food utilization |
| US4497795A (en) * | 1982-12-13 | 1985-02-05 | The Texas A&M University System | Method of regulating appetite and efficiency of food utilization employing interferon |
| EP0173935A1 (en) * | 1984-08-31 | 1986-03-12 | University Patents, Inc. | Hybrid lymphoblastoid-leukocyte human interferons |
-
1984
- 1984-09-19 DE DE19843434345 patent/DE3434345A1/de not_active Withdrawn
-
1985
- 1985-09-12 EP EP85111556A patent/EP0175289A3/de not_active Withdrawn
- 1985-09-17 NZ NZ213501A patent/NZ213501A/en unknown
- 1985-09-17 GR GR852254A patent/GR852254B/el unknown
- 1985-09-17 PH PH32795A patent/PH22650A/en unknown
- 1985-09-17 ES ES547044A patent/ES8702148A1/es not_active Expired
- 1985-09-18 ZA ZA857147A patent/ZA857147B/xx unknown
- 1985-09-18 JP JP60204574A patent/JPS6178732A/ja active Pending
- 1985-09-18 PT PT81147A patent/PT81147B/pt unknown
- 1985-09-18 DK DK423385A patent/DK423385A/da not_active Application Discontinuation
- 1985-09-18 AU AU47587/85A patent/AU579184B2/en not_active Ceased
- 1985-09-19 IL IL76433A patent/IL76433A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6178732A (ja) | 1986-04-22 |
| DK423385A (da) | 1986-03-20 |
| DE3434345A1 (de) | 1986-03-27 |
| EP0175289A2 (de) | 1986-03-26 |
| AU4758785A (en) | 1986-03-27 |
| EP0175289A3 (de) | 1987-11-19 |
| PT81147B (de) | 1987-03-30 |
| DK423385D0 (da) | 1985-09-18 |
| ZA857147B (en) | 1986-05-28 |
| ES8702148A1 (es) | 1986-12-16 |
| PH22650A (en) | 1988-10-28 |
| ES547044A0 (es) | 1986-12-16 |
| IL76433A0 (en) | 1986-01-31 |
| GR852254B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1986-01-17 |
| AU579184B2 (en) | 1988-11-17 |
| PT81147A (de) | 1985-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5906816A (en) | Method for treatment of autoimmune diseases | |
| AU698410B2 (en) | Use of interleukin-12 to prevent graft versus host disease | |
| JP2631470B2 (ja) | 感染防御剤 | |
| Brunda et al. | Inhibition of experimentally‐induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastases | |
| EP0333174A3 (en) | Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same | |
| IL94052A (en) | Pharmaceutical preparations containing cytokines for the treatment of pre-neoplastic lesions and the use of the above cytokines | |
| EP0741577A1 (en) | The use of interferon subtypes in the preparation of medicaments to treat viral infections | |
| EP0552243B1 (en) | Use of il-4 to treat solid tumors | |
| EP0128009B1 (en) | Synergistic composition comprising gamma interferon and lymphotoxin, and its preparation | |
| IL98910A0 (en) | Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them | |
| EP0299745A2 (en) | Double-stranded RNA correction of RNase L deficiency | |
| NZ213501A (en) | Pharmaceutical compositions containing alpha-interferons | |
| JP3266248B2 (ja) | 傷害を処置するための方法及び組成物 | |
| WO2004022088A1 (en) | Interferon and immunoglobulin fc fragment hybrid | |
| CA2241941C (en) | Therapeutic agent containing .omega.-feline interferon for treating feline aids virus infections and feline atopic dermatitis | |
| MXPA04008573A (es) | Agentes para la terapia preventiva despues de un accidente cerebrobascular agudo. | |
| Bubenik et al. | Local treatment with human recombinant interleukin 2 inhibits growth of MC-induced sarcomas in syngeneic mice | |
| KR0126677B1 (ko) | 항바이러스성 약제학적 조성물 | |
| Kurzrock et al. | Hairy cell leukaemia: review of treatment | |
| Starkebaum | Use of colony-stimulating factors in the treatment of neutropenia associated with collagen vascular disease | |
| EA009604B1 (ru) | ПРИМЕНЕНИЕ МУТАНТНОГО ПОЛИПЕПТИДА β-ЦЕПИ РЕЦЕПТОРА ИНТЕРФЕРОНА ТИПА I ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА, МОДУЛИРУЮЩЕГО ЭФФЕКТЫ ИНТЕРФЕРОНА-β, И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ УКАЗАННЫЙ ПОЛИПЕПТИД | |
| Kohl | Stimulation of human natural killer cytotoxicity and protection of mice from infection due to herpes simplex virus by recombinant human leukocyte interferon | |
| EP0055885A2 (en) | Novel insulin formulations | |
| Chang et al. | Activity of roxithromycin against Toxoplasma gondii in murine models | |
| EP1250147B1 (en) | Interferon-alpha use in the treatment of ewing's sarcoma |